Anti-Hypertensive Drugs - Malaysia

Malaysia

The Anti-Hypertensive Drugs market in Malaysia is projected to achieve a revenue of US$29.95m in 2024.
It is expected to display an annual growth rate (CAGR 2024-2028) of 0.52%, leading to a market volume of US$30.58m by 2028.
In comparison to other countries worldwide, United States is anticipated to generate the highest revenue of US$12,290.00m in 2024.
The demand for anti-hypertensive drugs in Malaysia is steadily increasing due to the rising prevalence of hypertension among the aging population.

Key regions: Germany, United States, France, China, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Anti-Hypertensive Drugs in Malaysia has been increasing over the years.

Customer preferences: Patients in Malaysia prefer Anti-Hypertensive Drugs that are affordable and have fewer side effects. They also prefer drugs that are easy to consume and have a longer shelf life. As a result, generic drugs are becoming more popular in the market.

Trends in the market: The Anti-Hypertensive Drugs market in Malaysia is expected to grow due to the increasing prevalence of hypertension among the population. The government is also taking steps to increase awareness about hypertension and its complications. This has resulted in an increase in the number of people seeking medical treatment for hypertension, which in turn has led to an increase in the demand for Anti-Hypertensive Drugs.

Local special circumstances: The Malaysian government has implemented a national healthcare system that provides affordable healthcare to the population. This has led to an increase in the number of people seeking medical treatment for hypertension. The government is also promoting the use of generic drugs in the market to make healthcare more affordable for the population.

Underlying macroeconomic factors: The Malaysian economy has been growing steadily over the years. This has led to an increase in the disposable income of the population, which in turn has led to an increase in the demand for healthcare services. The government is also investing in the healthcare sector to improve the quality of healthcare services in the country. These factors are expected to drive the growth of the Anti-Hypertensive Drugs market in Malaysia in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.